根据一份提交给美国证券交易委员会的文件，生物制药公司Aldeyra Therapeutics Inc计划在2026年第三季度结束前，就其干眼症治疗药物Reproxalap重新提交的新药申请，向美国食品药品监督管理局请求召开D类会议。此类会议通常旨在解决药物审评过程中出现的、需要FDA反馈的特定且有限的问题。此举标志着该公司在推动该候选药物获批的监管路径上迈出了明确的一步。
根据一份提交给美国证券交易委员会的文件，生物制药公司Aldeyra Therapeutics Inc计划在2026年第三季度结束前，就其干眼症治疗药物Reproxalap重新提交的新药申请，向美国食品药品监督管理局请求召开D类会议。此类会议通常旨在解决药物审评过程中出现的、需要FDA反馈的特定且有限的问题。此举标志着该公司在推动该候选药物获批的监管路径上迈出了明确的一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.